Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
This article discusses the 'top 10' considerations that health care providers should know about these novel combination therapies as these agents begin to gain an increasing presence in clinical practice.
PMID: 29521173 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
More News: Diabetes | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Health Management | Insulin | Internal Medicine | Lantus | Victoza